Salarius Pharmaceuticals Invested 2018

Salarius Pharmaceuticals is an emerging biotechnology company developing targeted therapies to treat pediatric and other cancers, including advanced solid tumors. Our lead compound Seclidemstat represents a potential paradigm shift in the treatment of cancer and we are initially targeting Ewing sarcoma, a devastating pediatric, adolescent and young adult bone cancer where no targeted therapies are currently available.


Looking for Funding?

VisionTech Partners may be able to help. Through VisionTech Angels and a broad network of investors and business resources, our goal is to help promising ventures succeed. We focus on early stage and early growth technology-based companies in Indiana and the Midwest.

If you have questions or would like more information, Contact Us. If you’re ready to start the process, Submit Your Business Plan using the secure website of Gust, the global platform for angel investing. We look forward to hearing from you!